Real-world registry of patients with unresectable hepatocellular carcinoma: The OREIOS study.

被引：0
|
作者：
Chan, Stephen Lam
Ryu, Min-Hee
Waked, Imam
Shao, Yu Yun
Tai, Wai Meng David
Breder, Valeriy
Alolayan, Ashwaq
Ganguly, Sandip
机构：
[1] Chinese Univ Hong Kong, Sir YK Pao Ctr Canc, Hong Kong, Peoples R China
[2] Univ Ulsan, Dept Oncol, Coll Med, Asan Med Ctr, Seoul, South Korea
[3] Menoufiya Univ, Natl Liver Inst, Shibin Al Kawm, Al Minufya, Egypt
[4] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[5] Natl Canc Ctr Singapore, Div Med Oncol, Expt Canc Therapeut Unit, Singapore, Singapore
[6] Russian Canc Res, Moscow, Russia
[7] King Abdulaziz Med City Cent Reg, Riyadh, Saudi Arabia
[8] Tata Med Ctr, Kolkata, India
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS618
引用
收藏
页码：TPS618 / TPS618
页数：1
相关论文
共 50 条
  • [1] Real-world survival outcomes and treatment patterns in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Results from the OREIOS study
    Chan, Stephen
    Breder, Valeriy Vladimirovich
    Shao, Yu Yun
    Tai, David
    Waked, Imam
    Ganguly, Sandip
    Alolayan, Ashwaq
    Aboutaleb, Ahmed
    Farag, Heba
    Ryu, Min-Hee
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 449 - 449
  • [2] Real-world efficacy and safety of donafenib-based therapies in patients with unresectable hepatocellular carcinoma: A retrospective study.
    Shang, Changzhen
    Luo, Xuan
    Zhong, Jinyi
    Zhang, Jianlong
    Li, Huilong
    Tan, Wenliang
    Lei, Zhang
    Chen, Yajin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] Efficacy and safety of TACE combined with ablation and regorafenib for unresectable hepatocellular carcinoma: A real-world study.
    Xiong, Yiqi
    Gao, WenFeng
    Long, Jiang
    Hu, CaiXia
    Yuan, ChunWang
    Sun, Yu
    Shi, QinSheng
    Sun, Bin
    Zhang, YingHua
    Cui, XiongWei
    Hao, MeiJun
    Li, Jianjun
    Zhang, Yonghong
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] Real-world dosing of regorafenib in patients with unresectable hepatocellular carcinoma (uHCC): Final analysis of the prospective, observational REFINE study.
    Finn, Richard S.
    Merle, Philippe
    Ikeda, Masafumi
    Klumpen, Heinz-Josef
    Masi, Gianluca
    Granito, Alessandro
    Lim, Ho Yeong
    Kudo, Masatoshi
    Qin, Shukui
    Gerolami, Rene
    Huang, Yi-Hsiang
    Kim, Do Young
    Pinter, Matthias
    Kato, Naoya
    Kurosaki, Masayuki
    Numata, Kazushi
    Khan, Javeed
    Ozgurdal, Kirhan
    Kim, Yoon Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 518 - 518
  • [5] Cryoablation versus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma with lenvatinib from a real-world study.
    Chang, Xiujuan
    Wang, Di
    Zhang, Wei
    Huang, Jiagan
    Zeng, Zhen
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : 54 - 54
  • [6] Lenvatinib plus pembrolizumab versus lenvatinib in patients with unresectable hepatocellular carcinoma: A real world study.
    Lee, I-Cheng
    Wu, Chi-Jung
    Chen, San-Chi
    Chao, Yee
    Huang, Yi-Hsiang
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] Real-world data in 1000 patients with unresectable hepatocellular carcinoma (HCC) treated with systemic therapy: Patient background in PRISM study.
    Ikeda, Masafumi
    Itoh, Shinji
    Tateishi, Ryosuke
    Yamashita, Tatsuya
    Okusaka, Takuji
    Kato, Naoya
    Furuse, Junji
    Kudo, Masatoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 566 - 566
  • [8] Efficacy and safety of durvalumab plus tremelimumab for unresectable hepatocellular carcinoma in Thailand: A real-world multicenter observational study.
    Korphaisarn, Krittiya
    Wirasorn, Kosin
    Tanasanvimon, Suebpong
    Thanasombunsukh, Kijjakom
    Maneenil, Kunlatida
    Thanestada, Jirawat
    Teeyapun, Nattaya
    Chindaprasirt, Jarin
    Sathitruangsak, Chirawadee
    Siripoon, Teerada
    Tiraswasdichai, Phannin
    Charonpongsuntorn, Chanchai
    Wanchaijiraboon, Passakorn
    Laosuangkoon, Wannisa
    Sunpaweravong, Patrapim
    Akewanlop, Charuwan
    TSCO GI Groups
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 539 - 539
  • [9] Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study
    Yue Han
    Guang Cao
    Bin Sun
    Jian Wang
    Dong Yan
    Haifeng Xu
    Qinsheng Shi
    Zechuan Liu
    Weihua Zhi
    Liang Xu
    Bojun Liu
    Yinghua Zou
    BMC Gastroenterology, 21
  • [10] Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study
    Han, Yue
    Cao, Guang
    Sun, Bin
    Wang, Jian
    Yan, Dong
    Xu, Haifeng
    Shi, Qinsheng
    Liu, Zechuan
    Zhi, Weihua
    Xu, Liang
    Liu, Bojun
    Zou, Yinghua
    BMC GASTROENTEROLOGY, 2021, 21 (01)
12345